A tumor is more than meets the eye
The microenvironment of cancers contains a combination of healthy cells, tumor cells, connective tissue, blood vessels, and inflammation in different ratios at different time points. Each of these components will have their own unique-molecular signature of compounds. Researchers who study disease states rely heavily on interpreting tissue pathology and creating these maps within the context of biomolecules bridges the gap between traditional OMICS and understanding disease.
Press release ASMS 2019
SpatialOMx – the key to biomarker discovery
Cancer cells and other disease states have significant genetic and epigenetic modifications that influence the genomic expression cascade. Whether you’re looking at the proteome, lipidome or metabolome, the spatial distribution of compounds contains valuable Information for understanding your sample. If certain compounds are highly spatially concentrated or if molecules are co-distributed on specific structures, this vital information is missing when only examining homogenized samples. OMICS based biomarker discovery can be limited without the benefit of spatial information to add important contextual clues as tissue-level communications networks are integral to cancer growth.
Bring a spatial dimension to X-Omics analyses
The timsTOF fleX is a versatile instrument for probing the molecular content of your sample. Built on Bruker’s pioneering timsTOF Pro platform, the timsTOF fleX is a fully functional high speed, high sensitivity ESI instrument for all your X-Omics analyses, combined with a high spatial resolution MALDI source and stage specifically designed for resolving molecular distributions and bringing a spatial dimension to OMICS analyses. Transform proteomics analysis into spatial proteomics, lipidomics into spatial lipidomics, and metabolomics into spatial metabolomics.